Related Experiment Video
Updated: May 3, 2026

A New Technique for Quantitative Analysis of Hair Loss in Mice Using Grayscale Analysis
Published on: March 9, 2015
Safety Profile of Baricitinib in Patients With Severe Alopecia Areata: A Prospective Study
Isotta Giunipero di Corteranzo1, Eleonora Bongiovanni1, Stephano Cedirian2,3
1Section of Dermatology, Department of Medical Sciences, University of Turin, Turin, Italy.
Introduction:
In adults, baricitinib, a Janus kinase (JAK)1/JAK2 inhibitor, is the first globally approved treatment for severe alopecia areata (AA). Its efficacy and safety were established in phase III trials, but real-life evidence remains limited.
Objective:
Our aim was to evaluate the real-life safety profile of baricitinib over 48 weeks in a clinical setting.
Methods:
A prospective observational study was conducted on 87 adult patients with severe AA at the University Hospital of Turin. Patients were treated with baricitinib at doses of 2 or 4 mg daily and were evaluated at baseline, 12, 24, 36, and 48 weeks. Adverse events (AEs) were carefully monitored, and disease severity was measured using the Severity of Alopecia Tool (SALT) score.
Results:
The cohort consisted of 71% females, with a mean age of 42 years and a mean baseline SALT score of 76.9. Baricitinib was generally well tolerated, with 20% of patients reporting AEs. The most common AEs were hypercholesterolemia (17%), hypertriglyceridemia (9.2%), and upper respiratory tract infections (5%). Two patients discontinued treatment due to neutropenia and recurrent infections. Most AEs were mild and manageable.
Conclusion:
Baricitinib shows a favorable safety profile in real-life clinical settings, aligning with findings from controlled clinical trials. The results support its use in routine clinical practice, though larger prospective studies are needed for further confirmation.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Bioavailability Study Design: Healthy Subjects Versus Patients
Bioequivalence studies: Biowaivers
Therapeutic Drug Monitoring: Affecting Factors

